Skip to main content
Erschienen in: BMC Surgery 1/2023

Open Access 01.12.2023 | Research

Breast conservation therapy decreased heart-specific mortality in breast cancer patients compared with mastectomy

verfasst von: Zhi Li, Ruipeng Zhao

Erschienen in: BMC Surgery | Ausgabe 1/2023

Abstract

Aim

To investigate the impacts of breast conservation therapy (BCT) and mastectomy on heart-specific mortality in breast cancer patients.

Methods

Patients with primary breast cancer registered in the Surveillance, Epidemiology, and End Results (SEER) database between Jan 1998 and Dec 2015 were included. Patients were divided into either breast conservation therapy or mastectomy group. To compare mortality caused by heart diseases in breast cancer patients with BCT or mastectomy, univariate and multivariate regression after propensity score matching (PSM) were performed. Kaplan-Meier analysis was also used to evaluate heart-specific survival between two groups.

Results

132,616 patients with breast cancer were enrolled in this study. After PSM, four risk factors including age, race, marital status and types of surgery were identified significantly associated with death from heart diseases. Heart-specific survival analysis further showed that overall, BCT poses a lower risk to heart-specific mortality compared with mastectomy.

Conclusion

Compared with mastectomy, BCT significantly decreased heart-specific mortality in breast cancer patients.
Hinweise
Acknowledgements.
Thank Qi Song for confirming the validity of the results .
Not applicable.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Introduction

Breast cancer is currently the most common women’s cancer, with an estimated 2 million new diagnosis in 2018 globally, and the fifth most common cause of mortality from cancer [1]. Progress made in treatment of breast cancer has largely improved the prognosis in breast cancer. A 41% reduction of mortality rate compared with that in 1990s was reported for 2021 [2]. However, despite better survival, complications from these treatments are also increasing. Studies have shown that patients with breast cancer could develop cardiovascular diseases (CVD) during treatment because of the cardiotoxicity from chemo-or radio-therapy and targeted therapy (e.g., anti-HER2 therapeutics) [36], and CVD has become an important factor in all-cause mortality of breast cancer patients [7]. Similarly, we analyzed the data from Surveillance, Epidemiology, and End Results Program (SEER) database and found that heart-specific is the second most common cause of death in patients with breast cancer. Furthermore, it was found that in elderly breast cancer patients, especially patients with preexisting heart diseases, heart-specific disease has become the leading cause of death, while breast cancer comes the second [8]. There is also evidence suggesting that other than age, race and cancer stage are also risk factors associated with CVD mortality [9].
Currently, surgery including mastectomy and breast conserving therapy (BCT), with chemoradiotherapy, endocrine therapy and molecular targeted therapy, is the standard of care in treating breast cancer [10]. Due to the development of radiotherapy, BCT is now more widely performed [11, 12]. No significant difference of prognosis, including overall survival and disease-free interval, was observed in previous studies, comparing BCT combining radiotherapy to mastectomy [1316].Recent results also showed that BCT might be more beneficial in terms of overall survival [17, 18]. Therefore, it was suggested BCT might be preferred over mastectomy. However, whether BCT and mastectomy would impact on heart-specific mortality in breast cancer patients is still unclear. Here, using SEER database, we assess the death resulted from heart disease in breast cancer patients who had underwent either BCT or mastectomy, to further demonstrate if the BCT would outweigh mastectomy regarding heart-specific survival.

Methods

Patients

The data were derived from the SEER database between Jan 1998 and Dec 2015 using SEER*Stat v8.3.5 software. Only patients with primary breast cancer were selected. The criteria are as followed: age at diagnose, sex, race, marital status, type of surgery, American Joint Committee on Cancer (AJCC) stage, estrogen receptor (ER) and progestogen receptor(PR) status, laterality, cause of mortality, survival time. The flow chart for entry conditions were shown in Fig. 1.

Statistical analysis

The primary endpoint is heart-specific survival (HSS), defined as the time between confirmed heart diseases diagnosis to death from them or last follow up. The heart diseases were listed in Table 1. Kaplan-Meier analysis was performed to estimate HSS. Cox proportional-hazards models were used to estimate hazard ratio and 95% confidence intervals within the same subgroup. Competing risk model was developed in R v3.6.2 via using package “cmprsk”, the primary endpoint of competing risk model is survival between the time at diagnosis of any diseases to death. The other analysis such as propensity score matching (PSM) were performed by SPSS 25.0. A p value less than 0.01 was considered significant.
Table 1
Heart-specific causes of death encoded with International Classification of Diseases 10 (ICD-10) codes in SEER database
Causes of Death
SEER Code
Medical Term
ICD-10 Code
Diseases of Heart
50,060
Ischaemic heart diseases
I20-I25
Hypertensive heart disease
I11, I13
Other forms of heart disease (e.g., heart failure)
I30-I51
Pulmonary heart disease and diseases of pulmonary circulation
I26-I28
Rheumatic heart disease
I00-I02, I05-I09

Results

Study population

A total of 132,616 patients were included in this study. The demographic and clinical characteristics were described in Table 2. Overall, 47,308 (35.7%) patients had mastectomy and 85,308 (64.3%) had BCT. The average follow-up time was 88.4 months. The mean age at diagnosis of breast cancer was 53.26 years old. Majority of the patients were white population (77.2%) and the black population only accounted for 13.2%, with the rest (including Latinos and Asians) being 9.3%. For AJCC stage, 89.2% of the patients were at either stage I or stage II when first diagnosed. More than half of patients were either ER or PR positive.
Table 2
Baseline of patients characteristics
characteristics
N = 132,616
Mastectomy
N = 47,308(35.7%)
N (%)
BCT
N = 85,308(64.3%)
N (%)
P value
Age at diagnosis (year)
    
≤50
55,601(41.9%)
22,378(47.3%)
33,223(38.9%)
<0.0001
>50
77,015(58.1%)
24,930(52.7%)
52,085(61.6%)
 
Race
    
White
102,334(77.2%)
35,967(76%)
66,367(77.8%)
<0.0001
Black
17,554(13.2%)
6440(13.6%)
11,114(13%)
 
Othersa
12,296(9.3%)
4768(10.1%)
7528(8.8%)
 
Unknown
432(0.3%)
133(0.3%)
299(0.4%)
 
AJCC Stage
    
I
32,445(24.5%)
1459(3.1%)
30,986(36.3%)
<0.0001
II
63,391(47.8%)
18,278(38.6%)
45,113(52.9%)
 
III
36,780(27.7%)
27,571(58.3%)
9209(10.8%)
 
ER status
    
Negative
40,443(30.5%)
13,641(28.8%)
26,802(31.4%)
<0.0001
Positive
92,173(69.5%)
33,667(71.2%)
58,506(68.6%)
 
PR status
    
Negative
54,425(41%)
18,956(40.1%)
35,469(41.6%)
<0.0001
Positive
78,191(59%)
28,352(59.9%)
49,839(58.4%)
 
Marital status
    
Married
83,098(62.7%)
29,055(61.4%)
54,043(63.4%)
<0.0001
Widowed
8460(6.4%)
3213(6.8%)
5247(6.2%)
 
Othersb
36,779(27.7%)
13,507(28.6%)
23,272(27.3%)
 
Unknown
4279(3.2%)
1533(3.2%)
2746(3.2%)
 
Laterality
    
Left
67,337(50.8%)
23,816(50.3%)
43,521(51%)
0.019
Right
65,279(49.2%)
23,492(49.7%)
41,787(49%)
 
a, other includes Latinos, Alaskan native, Asian, American Indian and Pacific Islander. b, others includes divorced, single and unmarried

Competing risk mortality

As shown in Fig. 2, heart-specific mortality was only second to breast cancer in terms of cause of mortality overall. Age-subgroup analysis further demonstrated that the risk of death from diseases of heart increased with age. In subgroup aged between 71 and 80, the mortality rate resulted from diseases of heart was higher than that caused by breast cancer after 13-year follow up. In subgroup aged 80 and over, after 8-year follow up, the heart-specific mortality rate was the leading cause of death, while breast cancer mortality ranked second.

Kaplan-Meier HSS in breast cancer patients

It showed that compared with HSS in mastectomy, HSS in BCT was significantly higher (P < 0.0001) (Fig. 3).

Risk factors for HSS identified by univariate and multivariate Cox analysis

As shown in Table 3,univariable analysis found that age, race, AJCC staging, ER and PR status, marital status, laterality and types of surgery were risk factors for HSS. Multivariable analysis was performed to further identify the variables mentioned above. Compared with patients aged no more than 50 at diagnosis, patients older than 50 were at a higher risk of heart-specific death (HR = 4.423, P < 0.0001). We also found that black populations had the highest risk of heart-specific mortality (HR = 1.647, P < 0.0001). Unsurprisingly, late stage posed a risk to death from heart disease (stage II: H = 1.348, P < 0.0001; stage III: HR = 1.935, P < 0.0001). No difference was observed between ER or PR status in heart-specific mortality. In terms of marital status, married patients were found to be less likely to die of heart-disease. Compared with BCT, mastectomy was significantly associated with higher risk of death from heart diseases(HR = 1.364, P < 0.0001).
Table 3
Cox proportional-hazards models of HSS
Variables
Univariable analysis
multivariable analysis
HR
95%CI
P value
HR
95%CI
P value
Age at diagnosis (year)
      
≤50
Ref
  
Ref
  
>50
4.972
4.305–5.742
<0.0001
4.423
3.818–5.123
<0.0001
Race
      
White
Ref
  
Ref
  
Black
1.74
1.525–1.987
<0.0001
1.647
1.438–1.886
<0.0001
Othersa
0.68
0.548–0.842
<0.0001
0.771
0.622–0.956
0.018
Unknown
0
0-1.45E + 33
0.836
0
0-3.02E + 37
0.852
AJCC Stage
      
I
Ref
  
Ref
  
II
1.444
1.254–1.663
<0.0001
1.348
1.166–1.557
<0.0001
III
2.467
2.132–2.855
<0.0001
1.935
1.63–2.297
<0.0001
ER status
      
Negative
Ref
  
Ref
  
Positive
0.806
0.724–0.898
<0.0001
0.892
0.766–1.038
0.138
PR status
      
Negative
Ref
  
Ref
  
Positive
0.742
0.67–0.822
<0.0001
0.874
0.758–1.009
0.066
Marital status
      
Married
Ref
  
Ref
  
Widowed
5.408
4.737–6.175
<0.0001
3.377
2.95–3.866
<0.0001
Othersb
1.525
1.352–1.721
<0.0001
1.45
1.283–1.64
<0.0001
Unknown
1.662
1.237–2.234
0.001
1.533
1.14–2.061
0.005
Laterality
      
Left
Ref
  
Ref
  
Right
0.976
0.881–1.08
0.634
0.977
0.883–1.082
0.659
Type of surgery
      
BCT
Ref
  
Ref
  
Mastectomy
1.703
1.535–1.888
<0.0001
1.364
1.204–1.545
<0.0001
a, other includes Latinos, Alaskan native, Asian, American Indian and Pacific Islander. b, others includes divorced, single and unmarried

K-M survival analysis and multivariable analysis after propensity score matching (PSM)

To adjust the imbalance between groups, PSM was performed to age, race, AJCC staging, ER and PR status, marital status and laterality (Table 4). Survival analysis after PSM showed HSS was significantly higher in BCT group compared with mastectomy (P = 0.0009) (Fig. 4). The same result was also observed after adjusting for the other variables (HR = 1.311, P < 0.001). In addition, age over 50 (HR = 4.001, p < 0.0001) and black population (HR = 1.855, p < 0.0001) were also found as risk factors for heart-specific death (Table 5), while being married was protective.
Table 4
Patient characteristics after PSM
Variables
N = 57,820
Mastectomy
N = 28,910
 N (%)
BCT
N = 28,910
 N (%)
P value
Age at diagnosis (year)
   
1
≤50
27,442(47.5%)
13,721(47.5%)
13,721(47.5%)
 
>50
30,378(52.5%)
15,189(52.5%)
15,189(52.5%)
 
Race
    
White
43,713(75.6%)
21,856(75.6%)
21,857(75.6%)
0.996
Black
8226(14.2%)
4115(14.2%)
4111(14.2%)
 
Othersa
5722(9.9%)
2858(9.9%)
2864(9.9%)
 
Unknown
159(0.3%)
81(0.3%)
78(0.3%)
 
AJCC Stage
    
I
2916(5%)
1458(5%)
1458(5%)
1
II
36,518(63.2%)
18,259(63.2%)
18,259(63.2%)
 
III
18,386(31.8%)
9193(31.8%)
9193(31.8%)
 
ER status
    
Negative
16,818(29.1%)
8409(29.1%)
8409(29.1%)
1
Positive
41,002(70.9%)
20,501(70.9%)
20,501(70.9%)
 
PR status
    
Negative
22,926(39.7%)
11,463(39.7%)
11,463(39.7%)
1
Positive
34,894(60.3%)
17,447(60.3%)
17,447(60.3%)
 
Marital status
    
Married
36,086(62.4%)
18,043(62.4%)
18,043(62.4%)
0.998
Widowed
3535(6.1%)
1768(6.1%)
1767(6.1%)
 
Othersb
16,337(28.3%)
8172(28.3%)
8165(28.3%)
 
Unknown
1862(3.2%)
927(3.2%)
935(3.2%)
 
Laterality
    
Left
29,114(50.4%)
14,554(50.4%)
14,560(50.4%)
0.960
Right
28,706(49.6%)
14,356(49.6%)
14,350(49.6%)
 
a, other includes Latinos, Alaskan native, Asian, American Indian and Pacific Islander. b, others includes divorced, single and unmarried
Table 5
Cox proportional-hazards models of HSS after PSM
Variables
Univariable analysis
Multivariable analysis
HR
95%CI
P value
HR
95%CI
P value
Age at diagnosis (year)
      
≤50
Ref
  
Ref
  
>50
4.786
3.921–5.843
<0.0001
4.001
3.26–4.91
<0.0001
Race
      
White
Ref
  
Ref
  
Black
1.968
1.632–2.372
<0.0001
1.855
1.531–2.248
<0.0001
Othersa
0.709
0.519–0.969
0.031
0.86
0.629–1.176
0.345
Unknown
0
0-1.32E + 57
0.9
0
0-5.09E + 41
0.876
AJCC Stage
      
I
Ref
  
Ref
  
II
1.637
1.055–2.542
0.028
1.548
0.997–2.405
0.052
III
2.657
1.704–4.144
<0.0001
2.125
1.361–3.318
0.001
ER status
      
Negative
Ref
  
Ref
  
Positive
0.753
0.64–0.885
0.001
0.914
0.73–1.144
0.431
PR status
      
Negative
Ref
  
Ref
  
Positive
0.663
0.568–0.772
<0.0001
0.759
0.614–0.938
0.31
Marital status
      
Married
Ref
  
Ref
  
Widowed
5.442
4.438–6.672
<0.0001
3.326
2.702–4.095
<0.0001
Othersb
1.668
1.395–1.994
<0.0001
1.505
1.254–1.806
<0.0001
Unknown
1.611
1.024–2.534
0.039
1.467
0.932–2.309
0.098
Laterality
      
Left
Ref
  
Ref
  
Right
0.941
0.807–1.096
0.433
0.941
0.817–1.099
0.441
Type of surgery
      
BCT
Ref
  
Ref
  
Mastectomy
1.367
1.173–1.594
<0.0001
1.311
1.125–1.529
0.001
a, other includes Latinos, Alaskan native, Asian, American Indian and Pacific Islander. b, others includes divorced, single and unmarried

Discussion

To provide a high-quality and patient-centered care, more attention should also be paid to health issues beyond breast cancer during treatment. This study is a large retrospective cohort study. In this study, we identified that heart-specific mortality is high in breast cancer patients, only second to breast cancer itself.
It was reported that the confirmation and treatment of breast cancer would induce posttraumatic stress disorder (PTSD), which has been known highly associated with death from coronary heart diseases and cardiovascular events [1924]. That is, breast cancer could have a negative impact on cardiovascular health.
In line with previous studies[2527], older breast cancer patients were more likely to die of heart diseases rather than breast cancer, and such risk increased with age. Previously, Safford et al. showed that compared with others (e.g., white, Asian and Hispanic women), black women experienced a higher risk of death from heart diseases [28]. The mortality rate was also higher in black females after taking treatment into account [29]. In this study, we also found the black women had a higher heart-specific mortality than the others. There might be several reasons for that, such as lower social-economic status. In terms of marital status, married women had the lowest risk. As reported by Dupre et al. [30], among patients with acute myocardial infarction, married patients had the lowest risk of death compared with other marital statuses. Schaal S et al. [31]suggested that widowhood could cause depression combined with PTSD which has been deemed a risk factor for coronary heart disease [23]. Besides, McGarry Kathleen et al. found that the number of widowhood below the poverty threshold was three times that of matrimony, which retained them from seeking better medical treatment [32, 34]. Therefore, lack of both psychological and financial support from partners also could pose a higher risk to heart-specific death.
In this study, patients with BCT were found to have a lower risk of death from heart diseases than patients with mastectomy. It might because BCT is less traumatic and takes a shorter recovery time postoperatively. A study by Šimunović, M. et al. suggested that patients who underwent BCT had lower trauma stress response scores [33]. It might also easier for BCT patients to return to normal life as less changes would be made to breast. A study including 3233 women with breast cancer by Flanagan, M. R. et al. showed that compared with patients with mastectomy, BCT patients had a higher satisfaction rate and higher quality of life [34, 13].
Regarding the surgical aspect, studies are not conclusive as to the improved survival rates in metastatic breast cancer patients undergoing resection [35].In this study, the risk of death attributable to heart diseases was higher in late stage breast cancer. That might be due to more chemoradiotherapy and higher doses they had received, leading to more iatrogenic cardiotoxicity, and more PTSD as well.
Interestingly, while it has been recognized that estrogen has a protective effect on cardiovascular system and anti-estrogen therapy may thus negatively impact on that [36, 37], It was also reported correlations between endocrine pathologies as negative prognostic factors both for breast cancer progression and survival [38],our study showed no significant difference in the risk of death from heart diseases between ER or PR positive and negative subgroups. More research may be required to clarify the underlying mechanisms.
This study also has some limitations. First, this study is a retrospective study so the data quality and reliability may be limited. Second, it is confirmed that chemotherapy and targeted therapy can cause either early or delayed cardiotoxicity, especially anthracyclines and Trastuzumab. However, due to lack of data about chemotherapy regimens and use of Trastuzumab in SEER database, we were not able to further explore the effect of chemotherapeutics and Trastuzumab on heart-specific mortality [3944]. What’s more, while comorbidities such as diabetes and hypertension that could also contribute to heart diseases, our study didn’t include these preexisting conditions because of insufficient data from SEER.

Conclusion

To conclude, our study showed that compared with mastectomy, BCT posed a significantly lower risk of heart-specific mortality. Age, race, stage and marital status were also important risk factors of death caused by heart diseases .

Declarations

Competing interests

The authors declare no competing interests.

Conflict of interest

This article has never been shown / published in any publication before form. All authors declare that there is no conflict of interest.

Ethics statement

The study was approved by the insititutional review board (CWO) of The Affiliated Huaian No. 1 People’s Hospital of Nanjing Medical University,approval number was KY-P-201900701.
Not applicable.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Acknowledgements.
Thank Qi Song for confirming the validity of the results .
Not applicable.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Freddie, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians; 2018. Freddie, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians; 2018.
2.
Zurück zum Zitat Siegel RL et al. Cancer Statistics, 2021. CA Cancer J Clin, 2021. 71(1): p. 7–33. Siegel RL et al. Cancer Statistics, 2021. CA Cancer J Clin, 2021. 71(1): p. 7–33.
3.
Zurück zum Zitat Matthews AA, et al. Endocrine therapy use and cardiovascular risk in postmenopausal breast cancer survivors. Heart. 2021;107(16):1327–35.CrossRefPubMed Matthews AA, et al. Endocrine therapy use and cardiovascular risk in postmenopausal breast cancer survivors. Heart. 2021;107(16):1327–35.CrossRefPubMed
4.
Zurück zum Zitat Chen J, et al. Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol. 2012;60(24):2504–12.CrossRefPubMed Chen J, et al. Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol. 2012;60(24):2504–12.CrossRefPubMed
5.
Zurück zum Zitat Rutqvist LE, et al. Cardiovascular mortality in a randomized trial of adjuvant radiation therapy versus surgery alone in primary breast cancer. Int J Radiat Oncol Biol Phys. 1992;22(5):887–96.CrossRefPubMed Rutqvist LE, et al. Cardiovascular mortality in a randomized trial of adjuvant radiation therapy versus surgery alone in primary breast cancer. Int J Radiat Oncol Biol Phys. 1992;22(5):887–96.CrossRefPubMed
6.
Zurück zum Zitat Barrett-Connor E, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355(2):125–37.CrossRefPubMed Barrett-Connor E, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355(2):125–37.CrossRefPubMed
7.
Zurück zum Zitat Ragaz J, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst. 2005;97(2):116–26.CrossRefPubMed Ragaz J, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst. 2005;97(2):116–26.CrossRefPubMed
8.
Zurück zum Zitat JL P, et al. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast cancer research: BCR. 2011;13(3):R64.CrossRef JL P, et al. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast cancer research: BCR. 2011;13(3):R64.CrossRef
9.
Zurück zum Zitat Weberpals J, et al. Long-term heart-specific mortality among 347 476 breast cancer patients treated with radiotherapy or chemotherapy: a registry-based cohort study. Eur Heart J. 2018;39(43):3896–903.CrossRefPubMed Weberpals J, et al. Long-term heart-specific mortality among 347 476 breast cancer patients treated with radiotherapy or chemotherapy: a registry-based cohort study. Eur Heart J. 2018;39(43):3896–903.CrossRefPubMed
10.
Zurück zum Zitat Gradishar WJ, et al. Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020;18(4):452–78.CrossRefPubMed Gradishar WJ, et al. Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020;18(4):452–78.CrossRefPubMed
11.
Zurück zum Zitat Jonczyk MM, et al. Surgical trends in breast cancer: a rise in novel operative treatment options over a 12 year analysis. Breast Cancer Res Treat. 2019;173(2):267–74.CrossRefPubMed Jonczyk MM, et al. Surgical trends in breast cancer: a rise in novel operative treatment options over a 12 year analysis. Breast Cancer Res Treat. 2019;173(2):267–74.CrossRefPubMed
12.
Zurück zum Zitat Lazovich D et al. Breast conservation therapy in the United States following the 1990 National Institutes of Health Consensus Development Conference on the treatment of patients with early stage invasive breast carcinoma Cancer, 1999. 86(4): p. 628 – 37. Lazovich D et al. Breast conservation therapy in the United States following the 1990 National Institutes of Health Consensus Development Conference on the treatment of patients with early stage invasive breast carcinoma Cancer, 1999. 86(4): p. 628 – 37.
13.
Zurück zum Zitat Jacobson J, et al. Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast Cancer. N Engl J Med. 1995;332(14):907–11.CrossRefPubMed Jacobson J, et al. Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast Cancer. N Engl J Med. 1995;332(14):907–11.CrossRefPubMed
14.
Zurück zum Zitat Veronesi U, et al. Breast conservation is the treatment of choice in small breast cancer: long-term results of a randomized trial. Eur J Cancer Clin Oncol. 1990;26(6):668–70.CrossRef Veronesi U, et al. Breast conservation is the treatment of choice in small breast cancer: long-term results of a randomized trial. Eur J Cancer Clin Oncol. 1990;26(6):668–70.CrossRef
15.
Zurück zum Zitat Fisher B, et al. Twenty-year follow-up of a Randomized Trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast Cancer. N Engl J Med. 2002;347(16):1233–41.CrossRefPubMed Fisher B, et al. Twenty-year follow-up of a Randomized Trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast Cancer. N Engl J Med. 2002;347(16):1233–41.CrossRefPubMed
16.
Zurück zum Zitat Veronesi U, et al. Comparing Radical Mastectomy with Quadrantectomy, Axillary Dissection, and Radiotherapy in patients with small cancers of the breast. N Engl J Med. 1981;305(1):6–11.CrossRefPubMed Veronesi U, et al. Comparing Radical Mastectomy with Quadrantectomy, Axillary Dissection, and Radiotherapy in patients with small cancers of the breast. N Engl J Med. 1981;305(1):6–11.CrossRefPubMed
17.
Zurück zum Zitat van Maaren MC, et al. 10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study. Lancet Oncol. 2016;17(8):1158–70.CrossRefPubMed van Maaren MC, et al. 10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study. Lancet Oncol. 2016;17(8):1158–70.CrossRefPubMed
18.
Zurück zum Zitat Boniface JD, Szulkin R, Johansson A. Survival after breast conservation vs mastectomy adjusted for Comorbidity and Socioeconomic Status: a Swedish National 6-Year follow-up of 48 986 women. JAMA Surg, 2021. 156(13). Boniface JD, Szulkin R, Johansson A. Survival after breast conservation vs mastectomy adjusted for Comorbidity and Socioeconomic Status: a Swedish National 6-Year follow-up of 48 986 women. JAMA Surg, 2021. 156(13).
19.
Zurück zum Zitat Linda et al. Prevalence of posttraumatic stress disorder (PTSD) in women with breast cancer. J Psychosom Res, 2014. Linda et al. Prevalence of posttraumatic stress disorder (PTSD) in women with breast cancer. J Psychosom Res, 2014.
20.
Zurück zum Zitat Kazlauskiene J, Bulotiene G. Prevalence of post-traumatic stress disorder among lithuanian breast cancer patients and its risk factors. J Psychosom Res. 2020;131:109939.CrossRefPubMed Kazlauskiene J, Bulotiene G. Prevalence of post-traumatic stress disorder among lithuanian breast cancer patients and its risk factors. J Psychosom Res. 2020;131:109939.CrossRefPubMed
21.
Zurück zum Zitat Oliveri S, et al. PTSD symptom clusters associated with short- and long-term adjustment in early diagnosed breast cancer patients. Ecancermedicalscience. 2019;13:917.CrossRefPubMedPubMedCentral Oliveri S, et al. PTSD symptom clusters associated with short- and long-term adjustment in early diagnosed breast cancer patients. Ecancermedicalscience. 2019;13:917.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Voigt V, et al. Clinically assessed posttraumatic stress in patients with breast cancer during the first year after diagnosis in the prospective, longitudinal, controlled COGNICARES study. Psychooncology. 2017;26(1):74–80.CrossRefPubMed Voigt V, et al. Clinically assessed posttraumatic stress in patients with breast cancer during the first year after diagnosis in the prospective, longitudinal, controlled COGNICARES study. Psychooncology. 2017;26(1):74–80.CrossRefPubMed
23.
Zurück zum Zitat Boscarino JA. A prospective study of PTSD and early-age heart disease mortality among Vietnam veterans: implications for surveillance and prevention. Psychosom Med. 2008;70(6):668–76.CrossRefPubMedPubMedCentral Boscarino JA. A prospective study of PTSD and early-age heart disease mortality among Vietnam veterans: implications for surveillance and prevention. Psychosom Med. 2008;70(6):668–76.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat O’Donnell CJ, et al. Posttraumatic stress disorder and Cardiovascular Disease: state of the Science, Knowledge gaps, and Research Opportunities. JAMA Cardiol. 2021;6(10):1207–16.CrossRefPubMed O’Donnell CJ, et al. Posttraumatic stress disorder and Cardiovascular Disease: state of the Science, Knowledge gaps, and Research Opportunities. JAMA Cardiol. 2021;6(10):1207–16.CrossRefPubMed
25.
Zurück zum Zitat Ramos R, et al. The role of age in cardiovascular risk factor clustering in non-diabetic population free of coronary heart disease. Eur J Epidemiol. 2004;19(4):299–304.CrossRefPubMed Ramos R, et al. The role of age in cardiovascular risk factor clustering in non-diabetic population free of coronary heart disease. Eur J Epidemiol. 2004;19(4):299–304.CrossRefPubMed
26.
Zurück zum Zitat Jeor STS et al. Prevention Conference VII: Obesity, a worldwide epidemic related to heart disease and stroke: Group II: age-dependent risk factors for obesity and comorbidities Circulation, 2004. 110(18): p. 471-5. Jeor STS et al. Prevention Conference VII: Obesity, a worldwide epidemic related to heart disease and stroke: Group II: age-dependent risk factors for obesity and comorbidities Circulation, 2004. 110(18): p. 471-5.
27.
Zurück zum Zitat Frankel S, et al. Birthweight, body-mass index in middle age, and incident coronary heart disease. Lancet. 1996;348(9040):1478.CrossRefPubMed Frankel S, et al. Birthweight, body-mass index in middle age, and incident coronary heart disease. Lancet. 1996;348(9040):1478.CrossRefPubMed
28.
Zurück zum Zitat Safford MM, et al. Association of Race and Sex with Risk of Incident Acute Coronary Heart Disease events. J Emerg Med. 2012;308(17):1768–74. Safford MM, et al. Association of Race and Sex with Risk of Incident Acute Coronary Heart Disease events. J Emerg Med. 2012;308(17):1768–74.
29.
Zurück zum Zitat Manhapra A, et al. Relation of age and race with hospital death after acute myocardial infarction. Am Heart J. 2004;148(1):92–8.CrossRefPubMed Manhapra A, et al. Relation of age and race with hospital death after acute myocardial infarction. Am Heart J. 2004;148(1):92–8.CrossRefPubMed
30.
Zurück zum Zitat Dupre ME, Nelson A. Marital history and survival after a heart attack. Social Science & Medicine; 2016. pp. 114–23. Dupre ME, Nelson A. Marital history and survival after a heart attack. Social Science & Medicine; 2016. pp. 114–23.
31.
Zurück zum Zitat Schaal S, et al. Rates and risks for prolonged grief disorder in a sample of orphaned and widowed genocide survivors. BMC Psychiatry. 2010;10:55.CrossRefPubMedPubMedCentral Schaal S, et al. Rates and risks for prolonged grief disorder in a sample of orphaned and widowed genocide survivors. BMC Psychiatry. 2010;10:55.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Kathleen M, Schoeni RF. Widow(er) Poverty and Out-of-Pocket Medical Expenditures Near the End of Life J Gerontol B Psychol Sci Soc Sci, 2005(3): p. 3. Kathleen M, Schoeni RF. Widow(er) Poverty and Out-of-Pocket Medical Expenditures Near the End of Life J Gerontol B Psychol Sci Soc Sci, 2005(3): p. 3.
33.
Zurück zum Zitat Šimunović M, Ljubotina D. Prevalence, structure and predictors of posttraumatic stress disorder symptoms in croatian patients following breast Cancer. Psychiatr Danub. 2020;32(2):187–96.CrossRefPubMed Šimunović M, Ljubotina D. Prevalence, structure and predictors of posttraumatic stress disorder symptoms in croatian patients following breast Cancer. Psychiatr Danub. 2020;32(2):187–96.CrossRefPubMed
34.
Zurück zum Zitat Flanagan MR, et al. A comparison of patient-reported outcomes after breast-conserving surgery and mastectomy with Implant breast Reconstruction. Ann Surg Oncol. 2019;26(10):3133–40.CrossRefPubMedPubMedCentral Flanagan MR, et al. A comparison of patient-reported outcomes after breast-conserving surgery and mastectomy with Implant breast Reconstruction. Ann Surg Oncol. 2019;26(10):3133–40.CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Amabile MI et al. Locoregional surgery in metastatic breast Cancer: do concomitant metabolic aspects have a role on the management and prognosis in this setting? J Pers Med, 2020. 10(4). Amabile MI et al. Locoregional surgery in metastatic breast Cancer: do concomitant metabolic aspects have a role on the management and prognosis in this setting? J Pers Med, 2020. 10(4).
36.
Zurück zum Zitat Anderson GL, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the women’s Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701–12.CrossRefPubMed Anderson GL, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the women’s Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701–12.CrossRefPubMed
37.
Zurück zum Zitat Grodstein F, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 1996;335(7):453–61.CrossRefPubMed Grodstein F, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 1996;335(7):453–61.CrossRefPubMed
38.
Zurück zum Zitat Baldini E et al. Thyroid Diseases and breast Cancer. J Pers Med, 2022. 12(2). Baldini E et al. Thyroid Diseases and breast Cancer. J Pers Med, 2022. 12(2).
39.
Zurück zum Zitat Henry ML, et al. Cardiotoxicity and Cardiac Monitoring among Chemotherapy-Treated breast Cancer patients. JACC Cardiovasc Imaging. 2018;11(8):1084–93.CrossRefPubMedPubMedCentral Henry ML, et al. Cardiotoxicity and Cardiac Monitoring among Chemotherapy-Treated breast Cancer patients. JACC Cardiovasc Imaging. 2018;11(8):1084–93.CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Jousilahti P, et al. Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14 786 middle-aged men and women in Finland. Circulation. 1999;99(9):1165–72.CrossRefPubMed Jousilahti P, et al. Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14 786 middle-aged men and women in Finland. Circulation. 1999;99(9):1165–72.CrossRefPubMed
41.
Zurück zum Zitat Romond EH, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673–84.CrossRefPubMed Romond EH, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673–84.CrossRefPubMed
42.
Zurück zum Zitat Piccart-Gebhart MJ, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659–72.CrossRefPubMed Piccart-Gebhart MJ, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659–72.CrossRefPubMed
43.
Zurück zum Zitat Bang YJ, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97.CrossRefPubMed Bang YJ, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97.CrossRefPubMed
44.
Zurück zum Zitat von Minckwitz G, et al. Adjuvant pertuzumab and trastuzumab in early HER2-Positive breast Cancer. N Engl J Med. 2017;377(2):122–31.CrossRef von Minckwitz G, et al. Adjuvant pertuzumab and trastuzumab in early HER2-Positive breast Cancer. N Engl J Med. 2017;377(2):122–31.CrossRef
Metadaten
Titel
Breast conservation therapy decreased heart-specific mortality in breast cancer patients compared with mastectomy
verfasst von
Zhi Li
Ruipeng Zhao
Publikationsdatum
01.12.2023
Verlag
BioMed Central
Erschienen in
BMC Surgery / Ausgabe 1/2023
Elektronische ISSN: 1471-2482
DOI
https://doi.org/10.1186/s12893-023-02132-1

Weitere Artikel der Ausgabe 1/2023

BMC Surgery 1/2023 Zur Ausgabe

Häusliche Gewalt in der orthopädischen Notaufnahme oft nicht erkannt

28.05.2024 Häusliche Gewalt Nachrichten

In der Notaufnahme wird die Chance, Opfer von häuslicher Gewalt zu identifizieren, von Orthopäden und Orthopädinnen offenbar zu wenig genutzt. Darauf deuten die Ergebnisse einer Fragebogenstudie an der Sahlgrenska-Universität in Schweden hin.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.